Human cytochromes mediating gepirone biotransformation at low substrate concentrations

Biopharmaceutics and Drug Disposition

Volumn 24, Issue 2, 2003, Pages 87-94

  Greenblatt, David J ^a   von Moltke, Lisa L ^a   Giancarlo, Gina M ^a   Garteiz, Daniel A ^b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

Cytochromes P450; Gepirone; In vitro metabolism

Indexed keywords

1 (2 PYRIMIDINYL)PIPERAZINE; 2 HYDROXYGEPIRONE; 3' HYDROXYGEPIRONE; 5 HYDROXYGEPIRONE; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; DRUG METABOLITE; GEPIRONE; ISOENZYME; KETOCONAZOLE; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL REACTION KINETICS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG CLEARANCE; DRUG TRANSFORMATION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LIVER MICROSOME; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS;

BIOTRANSFORMATION; BUSPIRONE; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; MICROSOMES, LIVER; PIPERIDONES; PYRIMIDINES; SEROTONIN AGONISTS;

EID: 0037342086     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/bdd.340     Document Type: Article

References (26)

1. Fitton A, Benfield P. Gepirone in depression and anxiety disorders - an initial appraisal of its clinical potential. CNS Drugs 1994; 1: 388-398.
2. Richards JB, Seiden LS. A quantitative interresponse-time analysis of DRL performance differentiates similar effects of the antidepressant desipramine and the novel anxiolytic gepirone. J Exper Anal Behav 1991; 56: 173-192.
3. Detke MJ, Rickels M, Lucki I. Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacol 1995; 121: 66-72.
4. Feiger AD. A double-blind comparison of gepirone extended release, imipramine, and placebo in the treatment of outpatient major depression. Psychopharm Bull 1996; 32: 659-665.
5. Eison AS, Eison MS, Stanley M, Riblet LA. Serotonergic mechanisms in the behavioral effects of buspirone and gepirone. Pharm, Biochem Behav 1986; 24: 701-707.
6. von Moltke LL, Greenblatt DJ, Grassi JM, et al. Gepirone and 1-(2-pyrimidinyl)-piperazine in vitro: human cytochromes mediating transformation and cytochrome inhibitory effects. Psychopharmacol 1998; 140: 293-299.
7. Tay LK, Dixon JF, Sostrin MB, Farmen RH, Pittman KA. The site of gastrointestinal absorption of gepirone in humans. J Clin Pharmacol 1992; 32: 827-832.
8. Tay LK, Sciacca MA, Sostrin MB, Farmen RH, Pittman KA. Effect of food on the bioavailability of gepirone in humans. J Clin Pharmacol 1993; 33: 631-635.
9. von Moltke LL, Greenblatt DJ, Harmatz JS, Shader RI. Alprazolam metabolism in vitro: studies of human, monkey, mouse, and rat liver microsomes. Pharmacol 1993; 47: 268-276.
10. von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Duan SX, Harmatz JS, Shader RI. Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interactions in vivo. J Pharmacol Exper Ther 1994; 268: 1278-1283.
11. von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Harmatz JS, Shader RI. Inhibitors of alprazolam metabolism in vitro: Effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. British J Clin Pharmacol 1994; 38: 23-31.
12. von Moltke LL, Greenblatt DJ, Harmatz JS, et al. Triazolam biotransformation by human liver microsomes in vitro: Effects of metabolic inhibitors, and clinical confirmation of a predicted interaction with ketoconazole. J Pharmacol Exper Therapeut 1996; 276: 370-379.
13. von Moltke LL, Greenblatt DJ, Granda BW, et al. Nefazodone, meta-chlorophenylpiperazine, and their metabolites in vitro: Cytochromes mediating transformation, and P450-3A4 inhibitory actions. Psychopharmacol 1999; 145: 113-122.
14. von Moltke LL, Greenblatt DJ, Grassi JM, et al. Citalopram and desmethylcitalopram in vitro: Human cytochromes mediating transformation, and cytochrome inhibitory effects. Biol Psych 1999; 46: 839-849.
15. Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism in humans: Clinical relevance. Clin Pharmacokinet 2000; 38: 111-180.
16. Crespi CL. Xenobiotic-metabolizing human cells as tools for pharmacological and toxicological research. Adv Drug Res 1995; 26: 179-235.
17. Crespi CL and Penman BW. Use of cDNA-expressed human cytochrome P450 enzymes to study potential drug-drug interactions. Adv Pharmacol 1997; 43: 171-188.
18. Crespi CL and Miller VP. The use of heterologously expressed drug metabolizing enzymes-state of the art and prospects for the future. Pharmacol Therapeut 1999; 84: 121-131.
19. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exper Therapeut 1994; 270: 414-423.
20. Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Relative quantities of catalytically active CYP 2C9 and 2C19 in human liver microsomes: Application of the relative activity factor approach. J Pharm Sci 1998; 87: 845-853.
21. Venkatakrishnan K, Greenblatt DJ, von Moltke LL, Schmider J, Harmatz JS, Shader RI. Five distinct human cytochromes mediate amitriptyline N-demethylation in vitro: Dominance of CYP 2C19 and 3A4. J Clin Pharmacol 1998; 38: 112-121.
22. Venkatakrishnan K, von Moltke LL, Court MH, Harmatz JS, Crespi CL, Greenblatt DJ. Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: Ratios of accessory proteins as sources of discrepancies between the approaches. Drug Metab Dispos 2000; 28: 1493-1504.
23. Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Application of the relative activity factor approach in scaling from heterologously expressed cytochromes P450 to human liver microsomes: Studies on amitriptyline as a model substrate. J Pharmacol Exper Therapeut 2001; 297: 326-337.
24. Störmer E, von Moltke LL, Greenblatt DJ. Scaling drug biotransformation data from cDNA-expressed cytochrome P-450 to human liver: A comparison of relative activity factors and human liver abundance in studies of mirtazapine metabolism. J Pharmacol Exper Therapeut 2000; 295: 793-801.
25. von Moltke LL, Greenblatt DJ, Giancarlo GM, Granda BW, Harmatz JS, Shader RI. Escitalopram (S-Citalopram) and its metabolites in vitro: Cytochromes mediating biotransformation, inhibitory effects, and comparison to R-Citalopram. Drug Metab Dispos 2001; 29: 1102-1109.
26. Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Human drug metabolism and the cytochromes P450: Application and relevance of in vitro models. J Clin Pharmacol 2001; 41: 1149-1179.